Read by QxMD icon Read

Multiple Sclerosis: Clinical and Laboratory Research

Gabriel Bsteh, Julia Feige, Rainer Ehling, Michael Auer, Harald Hegen, Franziska Di Pauli, Florian Deisenhammer, Markus Reindl, Thomas Berger
BACKGROUND: Stable disease course may prompt consideration of disease-modifying treatment (DMT) discontinuation in relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: To investigate the clinical outcome after DMT discontinuation and to identify predictive factors supporting decision-making. METHODS: We included 221 RRMS patients, who discontinued DMT after ⩾12 months and had documented follow-up ⩾2 years after discontinuation...
October 20, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Sung-Min Kim, Patrick Waters, Mark Woodhall, Yoo-Jin Kim, Jin-Ah Kim, So Young Cheon, Sehoon Lee, Seong Rae Jo, Dong Gun Kim, Kyeong Cheon Jung, Kwang-Woo Lee, Jung-Joon Sung, Kyung Seok Park
BACKGROUND: Neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G (NMOSD-AQP4) is an inflammatory disease characterised by a high female predominance. However, the effect of gender in patients with NMOSD-AQP4 has not been fully evaluated. OBJECTIVE: The aim of this study was to determine the effect of gender in clinical manifestations and prognosis of patients with NMOSD-AQP4. METHODS: The demographics, clinical and radiological characteristics, pattern reversal visual evoked potential (VEP) test results, and prognosis of 102 patients (18 males) with NMOSD-AQP4 were assessed...
October 19, 2016: Multiple Sclerosis: Clinical and Laboratory Research
W Oliver Tobin, Chiara Costanzi, Yong Guo, Joseph E Parisi, Stephen D Weigand, Claudia F Lucchinetti
BACKGROUND: The spectrum of central nervous system-idiopathic inflammatory demyelinating disease (CNS-IIDD) in the elderly is uncertain. OBJECTIVE: To describe the clinical, radiological, and pathological features of a cohort of 30 pathologically proven CNS-IIDD patients ⩾65 years. METHODS: Elderly multiple sclerosis (MS)/clinically isolated syndrome (CIS) patients were compared to a cohort of 125 patients with pathologically proven MS/CIS and symptom onset <65 years...
October 19, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Laura Airas, Eero Rissanen, Juha Rinne
Multiple sclerosis (MS) is a complex disease, where several processes can be selected as a target for positron emission topography (PET) imaging. Unlike magnetic resonance imaging (MRI), PET provides specific and quantitative information, and unlike neuropathology, it can be non-invasively applied to living patients, which enables longitudinal follow-up of the MS pathology. In the study of MS, PET can be useful for in vivo evaluation of specific pathological characteristics at various stages of the disease...
October 19, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Alessandro D'Ambrosio, Elisabetta Pagani, Gianna C Riccitelli, Bruno Colombo, Mariaemma Rodegher, Andrea Falini, Giancarlo Comi, Massimo Filippi, Maria A Rocca
OBJECTIVE: To investigate the role of cerebellar sub-regions on motor and cognitive performance in multiple sclerosis (MS) patients. METHODS: Whole and sub-regional cerebellar volumes, brain volumes, T2 hyperintense lesion volumes (LV), and motor performance scores were obtained from 95 relapse-onset MS patients and 32 healthy controls (HC). MS patients also underwent an evaluation of working memory and processing speed functions. Cerebellar anterior and posterior lobes were segmented using the Spatially Unbiased Infratentorial Toolbox (SUIT) from Statistical Parametric Mapping (SPM12)...
October 19, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Andrius Kavaliunas, Ali Manouchehrinia, Leszek Stawiarz, Ryan Ramanujam, Jonas Agholme, Anna Karin Hedström, Omid Beiki, Anna Glaser, Jan Hillert
OBJECTIVES: The aim of this study was to identify factors influencing the long-term clinical progression of multiple sclerosis (MS). A special objective was to investigate whether early treatment decisions influence outcome. METHODS: We included 639 patients diagnosed with MS from 2001 to 2007. The median follow-up time was 99 months (8.25 years). Cox regression models were applied to identify factors correlating with the outcome variable defined as time from treatment start to irreversible score 4 of the Expanded Disability Status Scale (EDSS)...
October 17, 2016: Multiple Sclerosis: Clinical and Laboratory Research
(no author information available yet)
Ahmad H, Taylor BV, van der Mei I et al. (2016). The impact of multiple sclerosis severity on health state utility values: Evidence from Australia. Mult Scler Epub ahead of print. DOI: 10.1177/1352458516672014.
October 17, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Anna M Pietroboni, Francesca Schiano di Cola, Marta Scarioni, Chiara Fenoglio, Barbara Spanò, Andrea Arighi, Sara Mg Cioffi, Emanuela Oldoni, Milena A De Riz, Paola Basilico, Alberto Calvi, Giorgio G Fumagalli, Fabio Triulzi, Daniela Galimberti, Marco Bozzali, Elio Scarpini
BACKGROUND: Neurodegeneration plays a major role in determining disability in multiple sclerosis (MS) patients. Hence, there is increasing need to identify reliable biomarkers, which could serve as prognostic measure of disease progression. OBJECTIVES: To assess whether cerebrospinal fluid (CSF) tau and β-amyloid (Aβ) levels were altered in newly diagnosed MS patients and correlated with disability. Moreover, we investigated whether these CSF biomarkers associate with macroscopic brain tissue damage measures...
October 17, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Luis Ruano, Emilio Portaccio, Benedetta Goretti, Claudia Niccolai, Milton Severo, Francesco Patti, Sabina Cilia, Paolo Gallo, Paola Grossi, Angelo Ghezzi, Marco Roscio, Flavia Mattioli, Chiara Stampatori, Maria Trojano, Rosa Gemma Viterbo, Maria Pia Amato
BACKGROUND: There is limited and inconsistent information on the clinical determinants of cognitive impairment (CI) in multiple sclerosis (MS). OBJECTIVE: The aim of this study was to compare the prevalence and profile of CI across MS disease subtypes and assess its clinical determinants. METHODS: Cognitive performance was assessed through the Brief Repeatable Battery and the Stroop test in consecutive patients with MS referred to six Italian centers...
October 13, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Robert J Fox
No abstract text is available yet for this article.
October 11, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Jeremy Chataway
No abstract text is available yet for this article.
October 11, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Daniel Ontaneda
No abstract text is available yet for this article.
October 11, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Anne Wickström, Maria Fagerström, Lucas Wickström, Gabriel Granåsen, Charlotte Dahle, Magnus Vrethem, Peter Sundström
BACKGROUND: Multiple sclerosis (MS) is a neurological disorder that causes significantly reduced ability to work, and the Expanded Disability Status Scale (EDSS) is one of the main predictors for reduced work ability. OBJECTIVES: To investigate how work requirements, flexible work conditions and disease-modifying drugs (DMDs) influence the work ability in relation to different EDSS grades in two MS populations. METHODS: Work ability was studied in two MS populations: one in the southern and one in the northern part of Sweden, both demographically similar...
October 6, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Nadja Borisow, Ingo Kleiter, Anna Gahlen, Katrin Fischer, Klaus-Dieter Wernecke, Florence Pache, Klemens Ruprecht, Joachim Havla, Markus Krumbholz, Tania Kümpfel, Orhan Aktas, Marius Ringelstein, Christian Geis, Christoph Kleinschnitz, Achim Berthele, Bernhard Hemmer, Klemens Angstwurm, Robert Weissert, Jan-Patrick Stellmann, Simon Schuster, Martin Stangel, Florian Lauda, Hayrettin Tumani, Christoph Mayer, Lena Zeltner, Ulf Ziemann, Ralf A Linker, Matthias Schwab, Martin Marziniak, Florian Then Bergh, Ulrich Hofstadt-van Oy, Oliver Neuhaus, Alexander Winkelmann, Wael Marouf, Lioba Rückriem, Jürgen Faiss, Brigitte Wildemann, Friedemann Paul, Sven Jarius, Corinna Trebst, Kerstin Hellwig
BACKGROUND: Gender and age at onset are important epidemiological factors influencing prevalence, clinical presentation, and treatment response in autoimmune diseases. OBJECTIVE: To evaluate the impact of female sex and fertile age on aquaporin-4-antibody (AQP4-ab) status, attack localization, and response to attack treatment in patients with neuromyelitis optica (NMO) and its spectrum disorders (neuromyelitis optica spectrum disorder (NMOSD)). METHODS: Female-to-male ratios, diagnosis at last visit (NMO vs NMOSD), attack localization, attack treatment, and outcome were compared according to sex and age at disease or attack onset...
October 6, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Jan-Mendelt Tillema, Stephen D Weigand, Jay Mandrekar, Yunhong Shu, Claudia F Lucchinetti, Istvan Pirko, John D Port
BACKGROUND: The relationship between cortical lesions (CLs) and white matter lesions (WMLs) in multiple sclerosis (MS) is poorly understood. Pathological studies support a topographical association between CLs and underlying subcortical WMLs and suggest CLs may play a role in both disease initiation and progression. We hypothesized that cortical MS lesions are physically connected to white matter MS lesions via axonal connections. OBJECTIVE: To assess the presence of CL-WML connectivity utilizing novel magnetic resonance imaging (MRI) methodology...
October 3, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Hasnat Ahmad, Bruce V Taylor, Ingrid van der Mei, Sam Colman, Beth A O'Leary, Monique Breslin, Andrew J Palmer
BACKGROUND: The measurement of health state utility values (HSUVs) for a representative sample of Australian people with multiple sclerosis (MS) has not previously been performed. OBJECTIVES: Our main aim was to quantify the HSUVs for different levels of disease severities in Australian people with MS. METHOD: HSUVs were calculated by employing a 'judgement-based' method that essentially creates EQ-5D-3L profiles based on WHOQOL-100 responses and then applying utility weights to each level in each dimension...
October 3, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Tomohiko Uchida, Masahiro Mori, Akiyuki Uzawa, Hiroki Masuda, Mayumi Muto, Ryohei Ohtani, Satoshi Kuwabara
BACKGROUND: Inflammation in neuromyelitis optica (NMO) is triggered by a serum antibody against the aquaporin-4 (AQP4). This process requires antibody penetration of the blood-brain barrier (BBB), but the mechanisms for BBB disruption in NMO remain unknown. OBJECTIVE: We examined whether changes in cerebrospinal fluid (CSF) and serum matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and cytokines are associated with BBB disruption in NMO...
September 28, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Julie Yoon Moberg, Bjarne Laursen, Nils Koch-Henriksen, Lau Caspar Thygesen, Anne Brødsgaard, Per Soelberg Sørensen, Melinda Magyari
BACKGROUND: Little is known about the consequences of parental multiple sclerosis (MS) on offspring's socioeconomic circumstances. OBJECTIVE: To investigate employment, disability pension and income in offspring of parents with MS compared with matched reference persons in a nationwide register-based cohort study. METHODS: All Danish-born persons with onset of MS during 1950-1986 were retrieved from the Danish Multiple Sclerosis Registry. Their offspring were identified using the Civil Registration System...
September 28, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Rosa E Boeschoten, Joost Dekker, Bernard Mj Uitdehaag, Aartjan Tf Beekman, Adriaan W Hoogendoorn, Emma H Collette, Pim Cuijpers, Magdalena M Nieuwenhuis, Patricia van Oppen
BACKGROUND: Depression in multiple sclerosis (MS) patients is common but may stay untreated. Physical limitations impede face-to-face treatment. Internet-based treatment is therefore a promising tool for treating depression in MS. OBJECTIVES: To investigate effectiveness of a guided Internet-based problem-solving treatment (IPST) for depressed MS patients. METHODS: MS patients with moderate or severe depressive symptoms were randomly assigned to IPST or a wait list control...
September 28, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Karen Ribbons, Rodney Lea, Clare Tiedeman, Laura Mackenzie, Jeannette Lechner-Scott
BACKGROUND: Since 1959, multiple sclerosis (MS) prevalence has been estimated for the east coast Australian city of Newcastle. Previous surveys, conducted in 1988 and 2003, have described an increase in the prevalence and incidence of MS. OBJECTIVES: In this study, we evaluated whether these trends continue and provide 50 years of MS epidemiological follow-up for this southern hemisphere city. METHODS: Expressed per 100,000 people, prevalence of MS in Newcastle was calculated for those with a confirmed diagnosis of MS on 9 August 2011 and incidence based on the number of cases with MS diagnosis made during the preceding decade...
September 28, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"